Myeloid leukemias are among the most aggressive blood cancers and have low survival rates. Today, leukemia patients undergo ...

A study demonstrates that the 'previous state' of blood stem cells plays a decisive role in the subtype of leukemia that develops. The new technique, called STRACK, allows monitoring of the evolution ...

▎药明康德内容团队编辑（来源：武汉大学）急性髓系白血病（AML）是一种由造血干/祖细胞遗传异常引发的血液系统恶性肿瘤，其致病因素主要包括染色体易位和基因突变等遗传变异。除急性早幼粒细胞白血病外，AML普遍存在治疗手段有限、复发率高、死亡率高等问题，导 ...

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

急性髓系白血病（AML）是一种常见的造血系统恶性肿瘤，其特征为未成熟白血病细胞在骨髓中的过度增殖，并伴随正常血细胞生成受阻。尽管近年来AML的治疗有所进展，但由于其高度异质性、疗效有限以及高复发率，AML患者的五年生存率依然较低。AML的病理机制研究 ...

After hours: February 21 at 5:57:25 PM EST Loading Chart for APVO ...

INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February ...